| Autor: |
Shoghli M; Department of Population Health, University of Helsinki, 00014 Helsinki, Finland., Lokki AI; Heart and Lung Center, Helsinki University Hospital, 00014 Helsinki, Finland.; Department of Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, 00014 Helsinki, Finland.; Department of Pathology, University of Helsinki, 00290 Helsinki, Finland., Lääperi M; Lääperi Statistical Consulting, 02770 Espoo, Finland., Sinisalo J; Heart and Lung Center, Helsinki University Hospital, 00014 Helsinki, Finland., Lokki ML; Department of Pathology, University of Helsinki, 00290 Helsinki, Finland., Hilvo M; VTT Technical Research Centre of Finland, 02044 Espoo, Finland., Jylhä A; Zora Biosciences Oy, 02620 Espoo, Finland., Tuomilehto J; Population Health Unit, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.; Department of Public Health, University of Helsinki, 00014 Helsinki, Finland.; Saudi Diabetes Research Group, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Department of International Health, National School of Public Health, Instituto de Salud Carlos III, 28029 Madrid, Spain., Laaksonen R; Zora Biosciences Oy, 02620 Espoo, Finland.; Finnish Cardiovascular Research Center, Tampere University Hospital, University of Tampere, 33521 Tampere, Finland. |
| Abstrakt: |
Ceramides and other sphingolipids are implicated in vascular dysfunction and inflammation. They have been suggested as potential biomarkers for hypertension. However, their specific association with hypertension prevalence and onset requires further investigation. This study aimed to identify specific ceramide and phosphatidylcholine species associated with hypertension prevalence and onset. The 2002 FINRISK (Finnish non-communicable risk factor survey) study investigated the association between coronary event risk scores (CERT1 and CERT2) and hypertension using prevalent and new-onset hypertension groups, both consisting of 7722 participants, over a span of 10 years. Ceramide and phosphatidylcholine levels were measured using tandem liquid chromatography-mass spectrometry. Ceramide and phosphatidylcholine ratios, including ceramide (d18:1/18:0), ceramide (d18:1/24:1), phosphatidylcholine (16:0/16:0), and the ratio of ceramide (d18:1/18:0)/(d18:1/16:0), are consistently associated with both prevalence and new-onset hypertension. Ceramide (d18:1/24:0) was also linked to both hypertension measures. Adjusting for covariates, CERT1 and CERT2 showed no-longer-significant associations with hypertension prevalence, but only CERT2 predicted new-onset hypertension. Plasma ceramides and phosphatidylcholines are crucial biomarkers for hypertension, with imbalances potentially contributing to its development. Further research is needed to understand the underlying mechanisms by which ceramides will contribute to the development of hypertension. |
